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Translocations involving the KMT2A (MLL) gene, located at 11q23, and two different 
partner genes, ELL and MLLT1, located at 19p13.1 and 19p13.3, respectively, have been 
reported in both acute myeloid leukemia (AML) and acute lymphoblastic leukemia 
(ALL).1,2 However, there are limited data describing clinical and molecular differences 
between adult patients with t(11;19)(q23;p13.1) and those with t(11;19)(q23;p13.3). Neither 
the Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer3 nor large 
studies correlating chromosome abnormalities with clinical outcome4 distinguish the two 
types of t(11;19); instead they combine both into one cytogenetic group. Herein, we report 
the largest, to our knowledge, series of 35 adults with acute leukemia and t(11;19)
(q23;p13.1) or t(11;19)(q23;p13.3) who were treated on Cancer and Leukemia Group B 
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(CALGB)/Alliance for Clinical Trials in Oncology (Alliance) trials. Our study is also the 
largest to describe the clinical features and disease outcomes of these patients as well as to 
provide mutational analyses, and gene- and microRNA (miR)-expression patterns, thereby 
providing the rationale to identify each as separate entities.
We identified and clinically characterized 19 adults with t(11;19) (q23;p13.1) and AML and 
16 with t(11;19)(q23;p13.3), 12 with AML, three with ALL and one with ambiguous lineage 
acute leukemia (ALAL), who received AML-directed therapy and is grouped with AML 
patients, enrolled onto a prospective cytogenetics companion trial, CALGB 8461. We also 
performed RNA, microRNA and targeted DNA-sequencing studies on subsets of patients in 
each cytogenetic group. See Supplementary Information for methods details.
Translocation (11;19)(q23;p13.1) was found exclusively in AML patients; however, t(11;19)
(q23;p13.3) was detected in both AML and ALL patients. The only significant clinical 
differences between AML patients with either translocation were the higher marrow (P = 
0.003) and blood (P = 0.004) blast percentages in patients with t(11;19)(q23;p13.3) (Table 
1). Among AML patients, there were no major differences between the two cytogenetic 
groups with respect to complete remission (CR) rates, disease-free survival or overall 
survival. Both translocations were associated with a poor prognosis, with a median overall 
survival of 8.2 months for t(11;19) (q23;p13.1) patients and 10.0 months for t(11;19)
(q23;p13.3) AML patients (Table 1, Supplementary Figure S1). The median follow-up for 
the four patients alive and without an event is 6.9 years.
Four (21%) t(11;19)(q23;p13.1) patients underwent either autologous (patients no. 3, 16) or 
allogeneic (no. 5, 6) hematopoietic stem-cell transplantation (HSCT) in CR1. Two (15%) 
AML patients with t(11;19)(q23;p13.3) received autologous (no. 30) or allogeneic (no. 25) 
HSCT in CR1. Three of these six patients remain alive and disease-free at last follow-ups of 
38.4 months (no. 6), 90.7 months (no. 25) and 134.3 months (no. 30) after diagnosis. 
Clinical and cytogenetic data for individual patients are provided in Supplementary Tables 
S1–S3.
We compared our findings with the literature and found them mostly concordant 
(Supplementary Tables S4 and S5). Others have also found t(11;19)(q23;p13.1) exclusively 
in AML patients, who were primarily female and had M4/M5 marrow morphology. 
However, t(11;19)(q23;p13.3) patients in the literature were mainly male, whereas two-
thirds of CALGB/Alliance patients with t(11;19) (q23;p13.3) were female.
Cytogenetically, t(11;19)(q23;p13.3) AML patients tended to have a higher incidence of 
secondary chromosome abnormalities at diagnosis than AML patients with t(11;19)
(q23;p13.1) (62% vs 26%, P=0.07). In most t(11;19)(q23;p13.1) patients (74%), the 
translocation was detected as an isolated chromosome abnormality; however, five patients 
had additional clonal abnormalities including trisomy 8 (+8), trisomy 21, paracentric 
inversion within 12p, deletion of 20q and a complex karyotype. The most common 
secondary abnormality was +8, found in six AML patients, but its incidence was higher 
among patients with t(11;19)(q23;p13.3) than those with t(11;19)(q23;p13.1) (83% vs 17%) 
(Supplementary Tables S1 and S2). In six of the seven patients for whom cytogenetic data 
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were available at the time of relapse, the translocation present at diagnosis was also found at 
relapse.
When we combined our data with the literature, secondary abnormalities occurred 
significantly more often in t(11;19) (q23;p13.3) patients (55% vs 21%, P < 0.001). Our data 
and the literature identified unbalanced structural abnormalities of 12p as novel recurrent 
secondary rearrangements. These 12p rearrangements, invariably leading to loss of 12p 
genetic material, were present at diagnosis in four patients (no. 29 and 30, cases reported by 
Ninomiya et al.5 and Cerveira et al.6), all with t(11;19)(q23; p13.3). A fifth patient with 
t(11;19)(q23;p13.3)7 and one patient with t(11;19)(q23;p13.1) (no. 17) acquired similar 
unbalanced 12p abnormalities at relapse. Notably, among adult patients, unbalanced 12p 
abnormalities were detected exclusively in patients diagnosed with AML.3
We next performed targeted DNA-sequencing studies in 13 AML patients with t(11;19)
(q23;p13.1) and eight patients with t(11;19)(q23;p13.3) (seven with AML and one with 
ALAL) to search for molecular differences between the two cytogenetic groups of AML 
patients (Figure 1a and Supplementary Table S6). In general, the mutation rate was low in 
both patient subsets using a variant allele frequency cutoff of 0.3 (Figure 1a). Whereas 
FLT3-TKD and mutations in KRAS, NRAS, CEBPA (single mutation) and TET2 were the 
only mutations observed in the t(11;19)(q23;p13.1) group, patients with t(11;19)(q23;p13.3) 
had a wider mutational spectrum. Specifically, t(11;19)(q23;p13.3) patients harbored 
mutations in ASXL1, ETV6, GATA2, KIT and TET2. Notably, we found no recurrent AML-
associated mutations such as double CEBPA mutations or mutations in DNMT3A, FLT3-
ITD, IDH1, IDH2, NPM1, TP53 or WT1 in either group. The relatively low number of gene 
mutations found in CALGB/Alliance patients is consistent with the findings reported by The 
Cancer Genome Atlas Research Network,8 in which patients with KMT2A fusions had the 
fewest number of recurrent mutations (with a mean of approximately two mutations in the 
coding regions of the genome (tier 1 mutations)) among 10 AML categories analyzed in that 
study. Our findings thus support the suggestion that gene fusions involving KMT2A, such as 
KMT2A-MLLT1 and KMT2A-ELL, require a smaller number of cooperating mutations 
than other AML-initiating genetic alterations.8
Stranded mRNA sequencing was performed on six AML patient samples with t(11;19)
(q23;p13.1) (no. 5, 6, 14, 15, 16, 18) and seven with t(11;19)(q23;p13.3) (six with AML (no. 
21, 24, 27, 28, 30, 31) and one with ALAL (no. 20)). Gene-expression profiles of t(11;19) 
(q23;p13.1) patients clustered tightly, whereas expression profiles of t(11;19)(q23;p13.3) 
patients were more diffuse and may represent two distinct subgroups (Figure 1b, 
Supplementary Figure S3). Of note, the outlier case (no. 20) was reconfirmed by 
cytogenetics and RNA-sequencing to harbor t(11;19)(q23;p13.3) (Supplementary Table S8).
Because the expression profiles of the t(11;19)(q23;p13.1) cases were very similar, a large 
number of protein-coding genes were found to be differentially expressed between 
cytogenetic groups at the 1% false discovery rate (q-value) level. To further enhance this, we 
eliminated the two cases clustering apart from their cytogenetic group (no. 16 and 20). Using 
a q-value cutoff of 0.01, a total of 690 genes were differentially expressed between the 
cytogenetic groups (Supplementary Table S9). We examined these 690 distinguishing genes 
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with Gene Set Enrichment Analysis9,10 to probe for biological differences between the two 
groups and observed that patients with t(11;19)(q23;p13.3) had a molecular profile with a 
more immature myeloid gene-expression pattern than patients with t(11;19)(q23;p13.1)11 
(Supplementary Figure S2).
In the context of disease response, 54 genes were differentially expressed between patients 
who achieved CR and those who did not, with 37 genes up- and 17 genes downregulated in 
patients who did not attain CR (Supplementary Table S10A). A repetition of this analysis 
after controlling for the translocation partner yielded a longer list of 72 genes 
(Supplementary Table S10B). Genes associated with failure to achieve CR were enriched for 
genes encoding zinc-finger transcription factors, many of which reside on the 19q arm. The 
biology of these, and other genes associated with CR attainment, should be explored in 
future studies. Consistent with prior reports,12,13 MECOM (EVI1) expression was observed 
in both our KMT2A-ELL and KTM2A-MLLT1 AML cases. None of five patients with 
MECOM overexpression achieved a CR, whereas six of eight patients with low MECOM 
expression did.
We also performed small RNA sequencing on six AML patient samples with t(11;19)
(q23;p13.1) and eight with t(11;19)(q23; p13.3) (seven with AML and one with ALAL). 
Again, these groups displayed distinct expression profiles; miR-expression profiling 
revealed 31 specific miRs that were differentially expressed between the cytogenetic groups. 
As with gene-expression, the miR-expression profiles clustered well overall (Figure 1c).
Lavallée et al.14 recently explored the transcriptomes of four patients with KMT2A-MLLT1 
(MLL-ENL) and three with KMT2A-ELL (MLL-ELL), and reported differing gene-
expression patterns between patients with and without KMT2A gene rearrangements. With 
our larger number of t(11;19) cases we were able to directly compare the transcriptional 
profiles of AML with KMT2A-MLLT1 and KMT2A-ELL fusions. Our results and those of 
Lavallée et al.14 support further exploration of biological differences between patients with 
KMT2A-MLLT1 and those with KMT2A-ELL.
In conclusion, our results add to the limited literature pertaining to t(11;19) in adults with 
acute leukemia and demonstrate that t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3) are indeed 
two distinct rearrangements associated with unique clinical and cytogenetic features. Both 
translocations, similar to the majority of other 11q23/KMT2A rearrangements, carry a poor 
prognosis, and both our study and published reports15 suggest that these patients should 
receive allogeneic HSCT in first remission. RNA-sequencing studies showed distinct gene- 
and miR-expression patterns between AML patients with t(11;19)(q23;p13.1) and those with 
t(11;19)(q23;p13.3) supporting the recognition of these two translocations as separate 
entities.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
(a) Oncoprint of pre-treatment gene mutations detected in t(11;19)(q23;p13.1) AML patients 
and t(11;19)(q23;p13.3) AML patients plus one with ambiguous lineage acute leukemia 
(ALAL) using a variant allele frequency cutoff of 0.3. Not marked is a single CEBPA 
mutation found in patient no. 13. (b) Principle component analysis plot depicting relative 
gene-expression profiles of six AML patients with t(11;19)(q23; p13.1), and six patients 
with AML plus one with ALAL (no. 20) harboring t(11;19)(q23;p13.3). Each dot represents 
one patient and is color-coded by translocation partner. X and Y axes: Euclidean distance 
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between gene-expression profiles in arbitrary units. (c) Heat map of the microRNA-
expression patterns of t(11;19)(q23;p13.1) AML patients versus those of AML patients, plus 
one with ALAL, with t(11;19)(q23;p13.3). The heat map shows expression levels of 31 
miRNAs found differentially expressed between t(11;19)(q23;p13.1) versus t(11;19)
(q23;p13.3) cases. Rows represent probe sets and columns individual patients. Patients are 
grouped according to t(11;19)(q23;p13.1) versus t(11;19)(q23; p13.3), and genes are ordered 
by hierarchical cluster analysis. Expression values of the probe sets are represented by color: 
blue represents expression less than the median value for the given probe set, and yellow, 
expression greater than the median value for the given probe set.
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Table 1
Comparison of clinical characteristics of patients with t(11;19) (q23;p13.1) and those with t(11;19)(q23;p13.3)
Characteristic t(11;19)
(q23;p13.1)
AML
(n = 19)
t(11;19)
(q23;p13.3)
AML
(n = 13)a
P-valueb t(11;19)(q23;p13.3)
ALL
(n=3)
Age, y 0.42
  Median 54 38 79
  Range 20–70 25–84 30–79
Age group, n (%) 1.00
  <60 y 13 (68) 9 (69) 1 (33)
  ≥60 y 6 (32) 4 (31) 2 (67)
Female sex, n (%) 11 (58) 9 (69) 0.71 3 (100)
Race, n (%) 1.00
  White 15 (83) 11 (85) 2 (67)
  Non-white 3 (17) 2 (15) 1 (33)
Hemoglobin, g/dl 0.51
  Median 9.1 9.5 12.5
  Range 2.8–15.8 6.2–12.0 7.7–13.8
Platelet count, × 109/l 1.00
  Median 49 56 66
  Range 16–163 20–184 11–165
WBC, × 109/l 0.14
  Median 29.4 10.0 92.5
  Range 2.1–97.5 2.3–80.7 11.8–231.9
Bone marrow blasts, % 0.003
  Median 57 87 90
  Range 26–93 45–96 65–94
Blood blasts, % 0.004
  Median 10 58 46
  Range 0–75 2–86 10–98
Therapy-related
leukemia, n (%)
0.20
  Yes 0 (0) 2 (15) 0 (0)
  No 19 (100) 11 (85) 3 (100)
FAB (centrally reviewed),
n (%)
— NR
  M0 0 (0) 1 (9)
  M1 1 (6) 1 (9)
  M2 3 (17) 0 (0)
  M4 7 (39) 0 (0)
  M5 7 (39) 6 (55)
  M6 0 (0) 0 (0)
  Other 0 (0) 3 (27)
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Characteristic t(11;19)
(q23;p13.1)
AML
(n = 19)
t(11;19)
(q23;p13.3)
AML
(n = 13)a
P-valueb t(11;19)(q23;p13.3)
ALL
(n=3)
Extramedullary
involvement, n (%)
5 (29) 3 (27) 1.00 0 (0)
Transplantation in CR1, n
(%)
1.00
  Allo 2 (11) 1 (8) 1 (33)
  Auto 2 (11) 1 (8) 0 (0)
  None 15 (78) 11 (85) 2 (67)
Translocation (11;19), n
(%)
0.07
  Occurring as a sole
  abnormality
14 (74) 5 (38) 2 (67)
  With additional
  abnormalities
5 (26) 8 (62) 1 (33)
Complete remission, n
(%)
9 (47) 8 (62) 0.49 2 (67)
Disease-free survival 0.78 2.1 and 7.9 mo
  Median, months 5.6 9.7
  % Disease-free at
  12 months, (95% CI)
33 (8–62) 25 (4–56)
  % Disease-free at
  60 months, (95% CI)
22 (3–51) 25 (4–56)
Overall survival 0.59 0.8, 5.2 and
8.8 mo
  Median, months 8.2 10.0
  % Alive at 12 months,
  % (95% CI)
21 (7–41) 46 (19–70)
  % Alive at 60 months,
  % (95% CI)
11 (2–28) 15 (2–39)
Abbreviations: allo, allogeneic hematopoietic stem-cell transplantation; auto, autologous hematopoietic stem-cell transplantation; CI, confidence 
interval; CR1, first complete remission, FAB, French-American-British classification; mo, months; n, number; NR, not reported; WBC, white blood 
count; y, years.
a
Includes one patient with ambiguous lineage acute leukemia.
bP-values for categorical variables are from Fisher’s exact test, P-values for continuous variables are from Wilcoxon rank sum test for comparisons 
between AML patients with t(11;19)(q23;p13.1) and those with t(11;19)(q23;p13.3).
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